Joint working has become something of the norm in the last decade, but have we taken the time to step back, take stock and see if we are doing it right?
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh